Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia.

Literature DB >> 19759558

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia.

D E Spaner, Y Shi, D White, S Shaha, L He, A Masellis, K Wong, R Gorczynski.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2009 PMID： 19759558 DOI： 10.1038/leu.2009.195

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

Review 1. Important aspects of Toll-like receptors, ligands and their signaling pathways.

Authors: Z L Chang
Journal: Inflamm Res Date: 2010-07-01 Impact factor: 4.575

Review 2. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

Authors: Abbi L Engel; Gregory E Holt; Hailing Lu
Journal: Expert Rev Clin Pharmacol Date: 2011-03 Impact factor: 5.045

3. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.

Authors: Brenda J Weigel; Sarah Cooley; Todd DeFor; Daniel J Weisdorf; Angela Panoskaltsis-Mortari; Wei Chen; Bruce R Blazar; Jeffrey S Miller
Journal: Am J Hematol Date: 2012-06-20 Impact factor: 10.047

4. Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation.

Authors: Brian Kornblit; Christian Enevold; Tao Wang; Stephen Spellman; Mike Haagenson; Stephanie J Lee; Klaus Müller
Journal: Biol Blood Marrow Transplant Date: 2014-11-20 Impact factor: 5.742

5. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.

Authors: Ying Tan; Amanda A Watkins; Benjamin B Freeman; John A Meyers; Ian R Rifkin; Adam Lerner
Journal: J Immunol Date: 2015-01-01 Impact factor: 5.422

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia.

Review 1. Important aspects of Toll-like receptors, ligands and their signaling pathways.

Review 2. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

3. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.

4. Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation.

5. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.

6. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia.

Review 7. Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands.

8. Toll-like Receptors in Chronic Lymphocytic Leukemia.

Review 9. Toll-like receptors in the pathogenesis of human B cell malignancies.

Review 10. Anti-tumor Activity of Toll-Like Receptor 7 Agonists.